IART INTEGRA LIFESCIENCES HOLDINGS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 917520 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.8%
TTM net income YoY102.6%
TTM EPS YoY102.6%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-49.5%
Margins
Gross margin52.4%
Operating margin4.4%
Net margin0.8%
FCF margin5.2%
EBITDA margin—
Returns
ROE1.2%
ROA0.4%
ROIC (approx.)2.8%
Asset turnover0.46x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity0.65x
Current ratio3.62x
Interest coverage0.79x
Cash quality & payout
Operating cash flow / net income10.79x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.64B | $1.61B |
| Cost of revenue | $803.62M | $728.47M |
| Gross profit | $831.62M | $882.06M |
| R&D expense | $98.97M | $115.38M |
| SG&A expense | $699.70M | $716.98M |
| Operating income | -$493.37M | $28.41M |
| Interest expense | $86.25M | $70.63M |
| Pretax income | -$563.50M | -$18.24M |
| Income tax | -$47.03M | -$11.29M |
| Net income | -$516.47M | -$6.94M |
| EBITDA | -$448.57M | $70.81M |
| EPS (basic) | -6.74 | -0.09 |
| EPS (diluted) | -6.74 | -0.09 |
| Weighted avg. shares (diluted) | 76.67M | 77.01M |
| Balance sheet | ||
| Cash & equivalents | $235.05M | $246.38M |
| Short-term investments | $28.69M | $27.19M |
| Receivables | $278.85M | $272.37M |
| Inventory | $492.74M | $429.09M |
| Current assets | $1.16B | $1.08B |
| PP&E, net | $444.33M | $405.72M |
| Goodwill | $615.16M | $1.10B |
| Intangibles | $1.13B | $1.21B |
| Total assets | $3.60B | $4.04B |
| Current liabilities | $455.98M | $922.13M |
| Long-term debt | $726.56M | $760.47M |
| Total debt | $726.56M | $760.47M |
| Total liabilities | $2.56B | $2.49B |
| Shareholders' equity | $1.04B | $1.55B |
| Net debt | $491.51M | $514.09M |
| Cash flow statement | ||
| Operating cash flow | $50.38M | $129.38M |
| Capital expenditure | $81.44M | $104.42M |
| Free cash flow | -$31.05M | $24.96M |
| Investing cash flow | -$108.06M | -$390.81M |
| Financing cash flow | $28.34M | $237.86M |
| Depreciation & amortization | $44.80M | $42.40M |
| Stock-based compensation | $18.58M | $24.38M |
| Share buybacks | $221,000 | $52.47M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.